Log in

2023 TACL Investigator Conference

Pic

Dear TACL Consortium Investigators and Research Team,

 

Thank you for attending and presenting at 2023 TACL Investigator Conference.  It was wonderful to see everyone in-person and virtually engaged in thoughtful discussions at the conference.

 

We would like to take few moments to share some highlights from the meeting as following:

 

The Investigator Conference was held at Dana-Farber Cancer Institute on October 15-17th with Opening Remarks and welcoming of attendees by Dr. Andrew Place, MD and Dr. Jessica Pollard, MD, Co-Chairs of the 2023 TACL Investigator Conference Planning Committee. 

 

On October 15th, the Pre-Main Conference Event, a TACL Operations update was given by Erika Shin-Kashiyama, followed by a TACL Leadership Overview by Dr. Alan Wayne, MD and Dr. Deepa Bhojwani, MD. Each of the TACL Sub-Committees then gave their own updates and reports. This Pre-Main Conference day concluded with a Welcome Reception for in-person attendees at Hilton Garden Inn Boston Brookline and was catered by the Punch Bowl Restaurant.

 

On October 16th, the Main Conference started with Mini-Symposium #1. This involved updates from various speakers on the Phase I AML/ALL clinical trial landscape at outside consortiums and institutions. Mini-Symposium #1 was followed by an outstanding keynote presentation by Dr. Kimberly Stegmaier, MD (DFCI) on novel target identification and validation. Mid-day included updates on current and developing TACL trials by their respective study chair’s. The Day 1 Main Conference presentations were concluded with Mini-Symposium #2, a fantastic talk from Dr. Wallace Bourgeois, MD on mechanisms of resistance to targeted agents. Later that evening, a wonderful professional networking meeting and dinner was held at the Barcelona-Brookline restaurant for all those who attended in-person.

 

On October 17th, the second day of the Main Conference started with Mini-Symposium #3 covering the development of novel immune effector cell therapies by Dr. Sarah Tasian, MD, Dr. Robbie Majzner, MD, and Dr. Jeffrey Bednarski, MD. Critical Topics discussion moderated by Dr. Andrew Place.  Dr. Jessica Pollard, and Dr. Deepa Bhojwani initiated the discussion by presenting “TACL Consortium: Where are we heading”, covering the future and goals of TACL. Finally, Dr. Wayne, Dr. Bhojwani, and Dr. Place concluded the Investigator Conference with a Wrap Up of three-day conference, a discussion on future planning, and closing remarks. 

 

During the three-day conference, presentations were very well received and led to many engaged open-forum discussions among presenters and attendees.  The conference had attendees from 25 sites in-person and 12 sites virtual.

Please note, do not disclose, or share contents of the confidential slides outside of TACL consortium member sites’ investigators and research teams is permitted.

 

TACL Operations Center is sincerely grateful to everyone's contribution and participation both in-person and virtually at the 2023 Investigators Conference, including Dr. Andrew Pace and Dr. Jessica Pollard for co-chairing the conference. Thank you all for your time, efforts, and continued dedication to TACL. 

 

We look forward to seeing everyone again at the next TACL Investigator Conference!

 

The 2023 TACL Investigator Conference was funded by Higgins Family Foundation.